T-cell receptor recognizing ID93-derived peptides (TCR-ID93)

T-cell receptors (TCRs) recognizing ID93-derived peptides are the primary molecular targets for the cellular immune response elicited by the ID93 tuberculosis vaccine candidate. ID93 is a recombinant fusion protein comprising four Mycobacterium tuberculosis (Mtb) antigens: Rv2608, Rv3619, Rv3620, and Rv1813, which are associated with Mtb virulence or latency [1]. These antigens are processed by antigen-presenting cells and presented on Major Histocompatibility Complex (MHC) Class I and Class II molecules to CD8+ and CD4+ T cells, respectively [2]. The interaction between the TCR and the peptide-MHC complex triggers T-cell activation, proliferation, and the secretion of Th1-type cytokines such as interferon-gamma (IFN-γ) and tumor necrosis factor (TNF) [3]. This specific immune recognition is designed to provide protective immunity against Mtb infection and prevent the progression of latent tuberculosis to active disease [1]. In clinical development, these TCRs serve as the functional targets for ID93-based vaccines, which are typically formulated with adjuvants like GLA-SE to enhance the magnitude and quality of the T-cell response [2]. Monitoring the frequency of T cells bearing these TCRs is a critical biomarker for evaluating vaccine efficacy and immunogenicity in clinical trials [3].

Other names

ID93-specific T-cell receptorMycobacterium tuberculosis antigen-specific T-cell receptorT-cell receptor recognizing Rv2608/Rv3619/Rv3620/Rv1813 peptides

Vaccine-induced activation of antigen-specific T cells via TCR recognition of peptide-MHC complexes